Ephedrine - Drug Note

Classification

• Class: Non-catecholamine sympathomimetic amine; mixed-acting adrenergic agonist
• Chemical: Noncatechol phenylisopropylamine (like amphetamine in structure)
• Isomers: Only l-ephedrine and racemic ephedrine are used clinically

Mechanism of Action

1. Direct action - directly stimulates α and β adrenergic receptors
2. Indirect action - enters presynaptic sympathetic nerve terminals via endocytosis and displaces norepinephrine (NE) from synaptic vesicles; the displaced NE activates postsynaptic α and β receptors

Receptor Profile

Pharmacokinetics (ADME)

Pharmacological Effects

• Cardiovascular: ↑ Blood pressure (systolic + diastolic), ↑ heart rate, ↑ contractility, ↑ cardiac output
• Respiratory: Bronchodilation via β2 activation
• CNS: Mild stimulant; raises MAC (minimum alveolar concentration for anesthetics)
• Urinary: Increased bladder outlet resistance (α1) - useful for urinary incontinence but can cause retention in BPH patients
• Uterine vasculature: Unlike pure α1 agonists, does NOT decrease uterine blood flow (sheep studies)

Clinical Uses

1. Vasopressor during anesthesia - most common use; treats intraoperative/spinal anesthesia-induced hypotension
2. Obstetric anesthesia - historically preferred over other vasopressors because it preserved uterine blood flow; now largely replaced by phenylephrine (faster onset, better fetal pH)
3. Bronchospasm/Asthma - now largely replaced by selective β2 agonists (salbutamol, etc.)
4. Urinary incontinence - increases bladder outlet tone via α1
5. Nasal decongestant (topical or oral)

Dosing (Clinical Anesthesia)

Adverse Effects

Tachyphylaxis

Comparison with Epinephrine

Drug Interactions / Regulatory Notes

• MAO inhibitors: Potentially serious interaction - indirect sympathomimetics (like ephedrine) can cause exaggerated pressor responses when NE metabolism is blocked
• Herbal (Ma Huang/Ephedra): Contains ephedrine and related alkaloids; FDA has banned ephedra-containing dietary supplements due to cardiovascular toxicity deaths
• Methamphetamine precursor: Ephedrine, pseudoephedrine, and phenylpropanolamine are regulated under the Combat Methamphetamine Epidemic Act (2005) due to illicit manufacturing potential
• Pseudoephedrine is a stereoisomer with similar decongestant properties, available OTC but quantity-restricted

Contraindications / Cautions

• Hypertension
• Coronary artery disease or unrecognized cardiovascular disease
• Benign prostatic hyperplasia (urinary retention risk)
• Concurrent MAO inhibitor use
• Hyperthyroidism

Key Comparison in Obstetrics (Recent Evidence)

Quick Memory Summary

"Ephedrine = Epi-lite" - similar effects to epinephrine (↑HR, ↑BP, bronchodilation) but oral, longer-lasting, weaker, mixed-acting, CNS-stimulating, and prone to tachyphylaxis.

Textbook Sources

1. Morgan & Mikhail's Clinical Anesthesiology, 7th Edition

• Section: EPHEDRINE (p. 451-452)
• ISBN: 9781260473797
• Used for: Mechanism of action, cardiovascular effects, anesthesia dosing (adults 2.5-10 mg, children 0.1 mg/kg), obstetric use vs. phenylephrine, tachyphylaxis, ampule availability

2. Goodman & Gilman's The Pharmacological Basis of Therapeutics

• Sections: "Ephedrine" + "ADME and Pharmacological Actions" + "Therapeutic Uses and Untoward Effects"
• ISBN: 9781264258079
• Used for: Receptor profile (α + β, mixed-acting), ADME (oral availability, t½ 3-6 h, renal elimination), clinical uses (asthma, urinary incontinence, spinal hypotension), adverse effects, FDA ephedra ban, Combat Methamphetamine Epidemic Act 2005

3. Katzung's Basic and Clinical Pharmacology, 16th Edition

• Section: Mixed-Acting Sympathomimetics (p. 235)
• ISBN: 9781260463309
• Used for: Historical context (2000+ years in China, introduced to Western medicine 1924), pharmacokinetic basis of long duration (non-catechol, not degraded by COMT/MAO), Ma huang herbal content, FDA ban

PubMed Source

Brenders A, Bleeser T, Deprest J. (2025)

• Title: Effect of vasoactive drugs used for management of hypotension during pregnancy on uterine hemodynamic parameters: a systematic review and meta-analysis
• Journal: Int J Obstet Anesth, Feb 2025
• PMID: 39580974
• Used for: Recent evidence supporting phenylephrine over ephedrine in obstetric spinal anesthesia

Ephedrine - Onset of Action

Key Points

• IV is the standard route in anesthesia for treating hypotension - the rapid onset makes it suitable for acute management, given as bolus doses of 5-10 mg
• IM/SC onset of 10-20 minutes is per the Pfizer (DBL Ephedrine Sulfate) official prescribing information
• Oral peak serum concentrations are reached within 2.6 to 3 hours, but bronchodilation begins within 15-60 minutes
• Despite rapid onset after IV, ephedrine's overall duration is much longer than epinephrine due to its non-catecholamine structure (not degraded by COMT or MAO)
• Phenylephrine is noted to have a faster onset than ephedrine in obstetric neuraxial anesthesia, which is one reason it has replaced ephedrine in that context

Sources for Ephedrine Onset of Action

1. Pfizer - DBL Ephedrine Sulfate Injection (Official Prescribing Information)

• URL: labeling.pfizer.com
• Used for: IM onset of 10-20 minutes; duration of 1 hour after IV (10-25 mg) or IM/SC (25-50 mg)
• Direct quote: "The onset of action after intramuscular administration is 10 to 20 minutes, and the duration of pressor and cardiac responses to ephedrine is 1 hour after intravenous administration of 10 to 25 mg or intramuscular or subcutaneous administration of 25 to 50 mg."

2. Drugs.com - Ephedrine Monograph (AHFS Drug Information)

• URL: drugs.com/monograph/ephedrine
• Used for: Oral onset (bronchodilation within 15-60 minutes); oral duration (2-4 hours bronchodilation, up to 4 hours pressor/cardiac); peak serum concentrations at 2.6-3 hours after oral dosing

3. Morgan & Mikhail's Clinical Anesthesiology, 7th Edition

• Section: EPHEDRINE (p. 451-452)
• ISBN: 9781260473797
• Used for: IV bolus dosing context in anesthesia; phenylephrine noted to have faster onset than ephedrine in obstetric neuraxial anesthesia

Note on IV Onset